Aprea Therapeutics (APRE) stock: insider trades, news & valuation
Net buyingShare price and insider trades
Aprea Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $50K and 0 sold $0 of APRE stock on the open market.
Get emailed when insiders cluster-buy stocks like APRE
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
APRE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | $30K | 2 | — | 0 |
| Q4 2025 | $31K | 2 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 Aprea Therapeutics, Inc. insiders reported open-market purchases totaling $50K, while 0 insiders reported sales totaling $0.
APRE earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 12, 2026 | +5.6% | None | +1.7%S&P +0.9% | +15.4% |
| May 13, 2026 | +4.5% | None | +4.6%S&P +1.4% | -27.1% |
| Mar 16, 2026 | -16.4% | None | +6.2%S&P +1.3% | +16.1% |
| Nov 12, 2025 | -1.5% | None | -9.8%S&P -1.6% | -21.4% |
| Aug 12, 2025 | -10.6% | None | +1.2%S&P +1.4% | -9.7% |
| May 14, 2025 | -14.3% | None | +20.0%S&P +0.6% | +2.2% |
| Mar 25, 2025 | -3.0% | None | -0.9%S&P -1.0% | -29.0% |
| Jan 13, 2025 | +8.5% | None | -1.0%S&P +0.3% | -2.5% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Feb 2SEC | Oren GiladCEO, President | Buy | 28,100373,720 held (+8%) | $0.89 | $25K | -32.1% | — |
| Feb 2SEC | John P. HamillCFO | Buy | 5,70033,433 held (+21%) | $0.89 | $5K | -32.1% | — |
| Dec 11SEC | Marc DueyDirector | Buy | 21,459256,155 held (+9%) | $1.17 | $25K | -48.4% | — |
| Dec 11SEC | John P. HamillCFO | Buy | 5,00027,733 held (+22%) | $1.17 | $6K | -48.4% | — |
Insiders at Aprea Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Marc DueyDirector | $25K | — | Dec 11, 2025 | — |
| Oren GiladCEO, President | $25K | — | Feb 2, 2026 | — |
| John P. HamillCFO | $11K | — | Feb 2, 2026 | — |
APRE stock: common questions
Are Aprea Therapeutics, Inc. insiders buying APRE stock?
In the past 12 months, 2 insiders reported open-market purchases of APRE worth $50K. The latest was CEO, President Oren Gilad bought $25K of APRE at $0.89 — first open-market purchase in our records.
Are Aprea Therapeutics, Inc. insiders selling APRE stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is APRE's 52-week range?
Over the past year APRE has traded between $0.56 and $1.65. It last closed at $0.60 on Oct 9, 2026.